Market News / Story
Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity study
MFN by Modular Finance ·
MFN by Modular Finance reports: STOCKHOLM — October 9, 2026 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma. Data from the first three treated patients demonstrate successful penetration of the human blood-brain barrier (BBB)…